IRIS UniCatt

Rossetti, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.165
AS - Asia 1.558
EU - Europa 1.385
SA - Sud America 303
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
Totale 5.504
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.063
SG - Singapore 688
CN - Cina 319
IT - Italia 261
BR - Brasile 240
FR - Francia 226
SE - Svezia 207
VN - Vietnam 155
DE - Germania 151
PL - Polonia 126
GB - Regno Unito 92
IN - India 89
IE - Irlanda 64
BD - Bangladesh 59
CA - Canada 54
ID - Indonesia 51
FI - Finlandia 47
JP - Giappone 44
ES - Italia 38
RU - Federazione Russa 32
ZA - Sudafrica 32
MX - Messico 31
UA - Ucraina 28
HK - Hong Kong 25
AR - Argentina 22
KR - Corea 20
IQ - Iraq 18
PT - Portogallo 18
AT - Austria 17
PH - Filippine 14
BE - Belgio 13
NL - Olanda 13
EC - Ecuador 12
LT - Lituania 12
TR - Turchia 12
CL - Cile 10
CM - Camerun 8
CO - Colombia 8
RO - Romania 8
IR - Iran 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
MA - Marocco 6
TN - Tunisia 6
TW - Taiwan 6
DZ - Algeria 5
GR - Grecia 5
UZ - Uzbekistan 5
VE - Venezuela 5
AU - Australia 4
CI - Costa d'Avorio 4
HR - Croazia 4
KE - Kenya 4
PK - Pakistan 4
BH - Bahrain 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
EU - Europa 3
JO - Giordania 3
LB - Libano 3
LV - Lettonia 3
MY - Malesia 3
NG - Nigeria 3
TH - Thailandia 3
UG - Uganda 3
AO - Angola 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
CZ - Repubblica Ceca 2
EG - Egitto 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MD - Moldavia 2
ML - Mali 2
NI - Nicaragua 2
PA - Panama 2
PY - Paraguay 2
AL - Albania 1
AM - Armenia 1
BO - Bolivia 1
BW - Botswana 1
GA - Gabon 1
GD - Grenada 1
GY - Guiana 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
MK - Macedonia 1
MM - Myanmar 1
MN - Mongolia 1
MQ - Martinica 1
NO - Norvegia 1
Totale 5.496
Salva come PNG Salva come JPEG
Città #
Singapore 370
Chandler 310
San Jose 216
Ashburn 196
New York 98
Kraków 97
Beijing 72
Milan 72
Dublin 62
Ho Chi Minh City 58
Los Angeles 55
Tokyo 44
Lauterbourg 43
Jakarta 41
Jacksonville 38
Redmond 36
Hanoi 35
The Dalles 34
Boston 33
Rome 32
San Mateo 32
Frankfurt am Main 31
Hefei 30
St Louis 30
Paris 29
London 28
Wilmington 26
Orem 25
Houston 24
Princeton 24
Munich 23
Helsinki 22
Marseille 22
Ann Arbor 21
Cattolica 21
Warsaw 21
Moscow 19
Nanjing 19
Johannesburg 18
Atlanta 17
Pune 17
Redwood City 17
Dearborn 16
Hong Kong 16
Chicago 15
Montreal 15
Catania 14
Dallas 14
Santa Clara 14
Seattle 14
Madrid 13
São Paulo 13
Brussels 12
Nuremberg 12
Tukwila 12
Brooklyn 11
Seoul 11
Council Bluffs 10
Da Nang 10
Haiphong 10
Manchester 10
Nanchang 10
Stockholm 10
Vienna 10
Fairfield 9
Kent 9
Norwalk 9
Ottawa 9
Phoenix 9
Poplar 9
Toronto 9
Boardman 8
Charlotte 8
Düsseldorf 8
San Francisco 8
Amsterdam 7
Brasília 7
Bremen 7
Buffalo 7
Dhaka 7
Lawrence 7
Miami 7
Mumbai 7
Turku 7
Woodbridge 7
Cusano Milanino 6
Davao City 6
Denver 6
Hebei 6
Lappeenranta 6
Mexico City 6
Porto 6
Queens 6
Turin 6
Washington 6
Bucharest 5
Changsha 5
Guangzhou 5
Hangzhou 5
Jeddah 5
Totale 2.980
Salva come PNG Salva come JPEG
Nome #
The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study 523
Whole-genome sequencing reveals host factors underlying critical COVID-19 223
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 191
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 183
An explainable model of host genetic interactions linked to COVID-19 severity 164
Cognitive reserve and neuropsychological functioning in older HIV-infected people 164
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 164
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 149
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 144
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 144
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 138
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 135
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 134
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 132
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 130
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 130
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 129
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience 126
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 125
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 123
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 121
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 120
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 119
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 118
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 114
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 114
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 113
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 112
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 109
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 105
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 105
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 102
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 101
Treatment of HCV infection with the novel NS3/4A protease inhibitors 98
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 98
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 94
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 89
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 84
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 79
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 78
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 75
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 68
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 8
Totale 5.575
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.089
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.089
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214 0 0 0 0 0 0 0 0 0 0 0 4
2021/2022258 12 2 4 19 7 11 13 50 8 26 34 72
2022/2023862 94 101 50 112 60 97 32 74 97 70 57 18
2023/2024562 27 107 28 39 36 124 31 25 24 24 38 59
2024/2025907 30 39 90 52 104 42 52 49 95 69 153 132
2025/20262.284 324 51 121 309 456 96 361 93 113 200 81 79
Totale 5.575